Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Revlar

Article

How will COVID-19 affect uptake of vaccinations against other diseases?

Research Partnership

- PMLiVE

Exploring the potential of eosinophils

GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils

- PMLiVE

GSK and Vir Biotech expand phase 3 COVID-19 antibody study

Study extends into additional sites after positive safety assessment

- PMLiVE

GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year

GSK is currently partnering with Sanofi on a COVID-19 vaccine project

- PMLiVE

Sanofi, GSK to launch human trials of COVID-19 vaccine

Vaccine combines Sanofi’s baculovirus expression system and GSK’s AS03 adjuvant

- PMLiVE

GSK doses first patients in phase 3 meningitis vaccine trial

Clinical programme will test five-in-one vaccine candidate

- PMLiVE

US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine

Both companies are also in talks with EU for access to candidate

Secondary effects of COVID-19 on the healthcare system and patients

We are getting to the point where we need to start considering the long-term effects on the healthcare system when making decisions.

Impetus Digital

- PMLiVE

UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

UK adds to its arsenal of potential vaccine candidates

- PMLiVE

GSK agrees on 10% equity stake in mRNA specialist CureVac

Equity investment totals £130m with an upfront payment of £104m

- PMLiVE

Novartis reveals full phase 3 results for Enerzair Breezhaler

Asthma treatment received EU approval earlier this week

- PMLiVE

GSK signs deal with Medicago for COVID-19 vaccine

Collaboration will utilise GSK’s pandemic adjuvant platform

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links